Amgen, Watson partner on ‘biosimilar’ growth drugs
THOUSAND OAKS, Calif. — The worlds biggest biotech company and a leading generic drugmaker are teaming up to give biosimilar versions of several biologic medicines on behalf of canker.Amgen Inc., a maker of biologic drugs pro plague, kidney disease and rheumatoid arthritis, says its partnering with Watson Pharmaceuticals Inc., which makes both generic medicines and branded drugs in support of womens shape and in support of urologic conditions.unruffled, they propose to develop and therefore market biosimilars, otherwise generic versions of biologic drugs, under a further combined Amgen/Watson brand.